natgillin/translations-raw huggingface dataset:
wherein, independently for each occurrence: is halogen, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen; 
R- je halogen ili skupina C,-C, alkil, pri čemu je navedena skupina C;-C; alkil supstituirana s 0-6 halogena;
The composition for the use of claim 7 or 8, wherein the composition further comprises a second cytomegalovirus vector comprising a fourth nucleic acid sequence that encodes a second heterologous antigen. 
Pripravak za upotrebu u skladu s patentnim zahtjevom7 ili 8, naznačen time, da pripravak nadalje sadržava drugi citomegalovirusni vektor koji sadržava četvrti sekvencijski slijed nukleinske kiseline koji kodira drugi heterologni antigen.
is selected from: 
R* je odabran od sljedećih:
Method according to claim 7, wherein the phase of detecting the current in at least a conductor connected to the load (16) is performed before and/or after the connection of the load (16) to the network (10). 
Postupak u skladu sa zahtjevom 11, naznačen time da se faza otkrivanja struje barem u vodiču spojenom na trošilo (16) obavlja prije i / ili poslije spajanja trošila (16) na mrežu (10).
At least one sunken seat 12 a comprises, at the opening 19 at which seat 12 a opens out at bottom face 3 a, a sunken annular edge 20 extending along the end portions of lateral walls 16; and a flat rectangular cover plate 22 is positioned with its peripheral edges 22 a resting along annular edge 20 to close opening 19 in fluidtight manner. 
Barem jedno upušteno sjedište 12a sadrži, kod otvora 19 kod kojeg se sjedište 12a otvara kod donjeg lica 3a, upušteni prstenasti rub 20 koji se prostire duž krajnjih dijelova bočnih stijenki 16; a ravna pravokutna pokrovna ploča 22 je smještena svojim obodnim rubovima 22a da počiva duž prstenastog ruba 20, da zatvori otvor 19 na hermetički način.
M represents zirconium (Zr), hafnium (Hf), or mixtures thereof; 
- M predstavlja cirkonij (Zr), hafnij (H), ili njihove smjese;
activating the antigen to form an activated antigen; a') lyophilising the activated antigen and a carrier protein followed by reconstitution in DMSO or DMF; reacting the activated antigen and the carrier protein to form an imine group linking the activated antigen to the carrier protein; and 
HR P20150587 T1 PATENTNI ZAHTJEVI Postupak konjugiranja antigena, naznačen time što se sastoji u koracima a) aktiviranja antigena kako bi se dobio aktivirani antigen; b) reakcije aktiviranog antigena s proteinskim nosačem kako bi se dobila iminska skupina koja povezuje aktivirani antigen s proteinskim nosačem; i
The node can be positioned in different parts of the air conditioning plant. 
POSTUPAK REGULIRANJA PROTOKA ZRAKA U SUSTAVU ZA KLIMATIZIRANJE ZRAKA | ODGOVARAJUĆI SUSTAV ZA KLIMATIZIRANJE ZRAKA
A method of treating a patient with an autoimmune ocular inflammatory disease (AOID), comprising administering to the patient an IL-17 antagonist. 
1IL-17 antagonist, naznačen time, da se koristi u liječenju pacijenta s autoimunom očnom upalnom bolesti (AOID). 2.
After reaction of the resin with the surface film to form the rotor blade or rotor blade element the resin therefore is to be interpreted as hardened unless otherwise stated in detail, in relation to the surface film, as the resin and the surface film have reacted with each other so that they are non-releasably joined together in the manner according to the embodiments of the invention as described in the opening part of this specification. 
"Metoda popravljanja za element oštrice rotora vjetroelektrane, koja uključuje korake u seriji: a) davanje vlaknastog materijala na elementu oštrice Totora, b) prekrivanje vlaknastog materijala površinskim filmom, c) opcionalno davanje vlaknastog materijala prekrivenog površinskim filmom tijelom za oblikovanje, te d) sisanje plina iz vlaknastog materijala, 6) primjenjivanje smole koja se može skrutnuti na vlaknasti materijal, i f) reagiranje smole koja se može skrutnuti sa površinskim filmom.
In further particular embodiments of the above embodiment, the Core is selected from the group consisting of: 
L je polialkilen glikolni linker; i Jezgra se bira iz skupine koju čine: j
Ar is phenyl or pyridyl, which is unsubstituted or mono- or disubstituted by Hal, LA or O(LA), or in Subformula 5 E is a methyl linker which is substituted by aminomethyl, wherein the amino group of the aminomethyl is unsubstituted, or mono- or disubstituted by LA, or E is a methyl linker which is substituted by (azetidin-1-yl)methyl, 
je Hal, LA, O(LA), Cyc1 ili Cyc2, ili u Podformuli 4 Ar je fenil ili piridil, koji je nesupstituiran ili mono- ili disupstituiran s Hal, LA ili O(LA), ili u Podformuli 5 E je metilna poveznica koja je supstituirana s aminometilom, pri čemu je amino skupina od aminometila nesupstituirana, ili mono- ili disupstituirana s LA, ili E je metilna poveznica koji je supstituirana s (azetidin-1-il)metil, ili u Podformuli 7 X je N, Y je N ili CH,
wherein R4 is C1-C4 linear alkyl or C3-C4 branched alkyl; or a pharmaceutically acceptable salt thereof; 
R* je Ci-Cu nerazgranati alkil ili C32-C, razgranati alkil; ili njegova farmaceutski prihvaljiva sol.
Membrane Binding Assays 3 
Ispitivanja vezanja na membranu 3
it does not inhibit TSLP-stimulated secretion of TARC in cells expressing the TSLP-R and/or, 
- - neinhibira TSLP-stimulirano izlučivanje TARC u stanicama koje eksprimiraju TSLP-R i/ili,
cd) KWRSALYRWRLWRSsALYSsR (SEQ ID NO: 18), and wherein the residues marked with a subscript "S" are the two residues linked by the hydrocarbon linkage. 
SEK.: 18), naznačeni time da su ostaci označeni donjim indeksom „S“ dva ostatka vezana ugljikovodičnom vezom.
The recombinant adenovirus of claim 1 or 2, wherein said transgene is tumor necrosis factor, kras, or a functional portion thereof. 
Rekombinantni adenovirus u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni transgen faktor nekroze tumora, kras ili njegov funkcionalni dio.
The apparatus as claimed in claim 5, wherein said flow rate detection means are arranged along said permeate outlet downstream of said third valve. 
Uređaj prema zahtjevu 5, naznačen time da su navedena sredstva za utvrđivanje protoka (17) postavljena uzduž navedenog izlaznog kruga permeata (18) nizvodno od navedenog trećeg ventila (16).
applying an electric field between two alignment electrodes over the layer, so that a number of the conductive particles are aligned with the field, thus creating conductive pathways, wherein at least one of the electrodes is not in direct contact with the layer while the electric field is applied; and changing the viscosity of the layer to a second viscosity, said second viscosity being higher than the first viscosity in order to mechanically stabilize the layer and preserve the conductive pathways, wherein a concentration of the conductive particles in the layer is below the percolation threshold. 
primjeni sloja smjese po prvoj površini, gdje smjesa ima prvu viskoznost, koja omogućuje premještanje vodljivih čestica u sloju; c. - primjeni električnog polja između dvije poravnavajuće elektrode preko sloja, tako da se više vodljivih čestica poravna s poljem, čime nastanu vodljivi putevi; d. - mijenjanje viskoznosti sloja u drugu viskoznost, gdje je navedena druga viskoznost veća od prve viskoznosti kako bi se mehanički stabiliziralo sloj i očuvalo vodljive puteve.
The method of any one of the preceding claims, wherein said level of sICAM-1 is measured with multi-analyte plasma protein profiling or enzyme-linked immunosorbant assays. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedenu razina sICAM-1 mjeri multianalitnim profilranjem proteina plazme ili imunosorpcijska ispitivanja vezana s enzimima.
under in vitro conditions in 900 mL artificial gastric juice at pH 1.2 and 37 ± 0.5°C after 30 minutes according to the paddle method with sinker at 100 rpm at least 50 wt.-% of the pharmacologically active agent, based on the total amount of the pharmacologically active agent originally contained in the pharmaceutical dosage form; and which comprises a solid polymeric matrix material in which the pharmacologically active agent according to general formula (I) is dispersed and immobilized in an amorphous or semi-amorphous state, and wherein the polymer is selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-polyvinylacetate copolymers, and any combinations thereof; and wherein the relative weight ratio of the polymer related to the pharmacologically active agent according to general formula (I) is at least 6:1. 
farmakološki aktivnog sredstva, u odnosu na ukupnu količinu farmakološki aktivnog sredstva koje je izvorno sadržano u farmaceutskom obliku doziranja; i koji sadrži kruti polimerni materijal matrice u kojem je farmakološki aktivno sredstvo prema općoj formuli (I) dispergirano i imobilizirano u amorfnom ili polu-amorfnom stanju, te pri čemu je polimer odabran iz skupine koju čine polivinilpirolidon, kopolimeri vinilpirolidon-polivinilacetat, te njihove bilo koje kombinacije; i pri čemu je relativni omjer mase polimera u odnosu na farmakološki aktivno sredstvo prema općoj formuli (I) barem 6:1.
"aryloxy" means an aryl-O- group in which the aryl group is as previously described wherein the bond to the parent moiety is through the ether oxygen; 
"ariloksi" znači skupina aril-O-, u kojoj arilna skupina je kao što je opisano ranije, gdje veza na osnovni ostatak jo preko eterskog kisika;
A combination for use according to any one of claims 1 to 3, wherein the B2 agonist is selected from the group comprising arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutaline, tulobuterol, GSK-597901, GSK-159797,KUL-1248,TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija sukladno patentnom zahtjevu 1 III 2, naznačena time, da je P2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuteroi, clenbuterol, dopeksamin, fenoterol, formoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)-formoterol, reproterol, ritodrin, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutalin, tulobuterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 i OAB-149, opcionalno u obliku njihovih racemata, eneantiomera, diastereomera i njihovih smjesa te opcionalno njihovih farmaceutski kompatibilnih kiselinskih adicijskih soli.
A composition for use according to Claim 1 or a composition as claimed in Claim 8, wherein the cyclodextrin is hydroxypropyl-B-cyclodextrin. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin hidroksipropil-f-ciklodekstrin.
The combined dichloromethane layers are washed with water (1x20 mL) followed by brine solution (1x20 mL) and dried over anhydrous Na2SO4. 
Pomiješane diklormetanske slojeve ispere se vodom (1 x 20 ml) i slanom otopinom (1 x 20 ml), te osuši preko bezvodnog Na2S0,.
The composition according to Claim 1 wherein the effective dosage amount or the therapeutically effective amount of cinacalcet HCl ranges from 1 mg to 360 mg, preferably from 5 mg to 240 mg, more preferably from 20 mg to 100 mg, or is chosen from 5 mg, 15 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 120 mg, 150 mg, 180 mg, 210 mg, 240 mg, 300 mg, and 360 mg. 
Smjesa prema zahtjevu 1 gdje je djelotvorna doza ili terapijski učinkovita količina sinakalcet HCI u rasponu od 1 mg do 360 mg, poželjno od 5 mg do 240 mg, poželjnije od 20 mg do 100 mg, ili se bira između 5 mg, 15 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 120 mg, 150 mg, 180 mg, 210 mg, 240 mg, 300 mg, i 360 mg. HR P20130114 T1
An apparatus for encoding a video, the apparatus comprising: a quantizer for performing quantization on coding units included in a slice segment, determining a slice-level initial quantization parameter (QP) for predicting a QP of a first quantization group of a parallel-decodable data unit included in the slice segment, obtaining a predicted QP of the first quantization group by using the determined slice-level initial QP, and outputting a difference between a QP used to perform quantization on a coding unit included in the first quantization group and the predicted QP, and the determined slice-level initial QP; and 
WPP sadrži proces u kojem se informacija o vjerojatnosti za entropijsko dekodiranje prve najveće jedinice kodiranja za nit određuje korištenjem informacija o vjerojatnosti za entropijsko dekodiranje druge najveće jedinice kodiranja gornje niti, pri čemu se predviđeni QP kvantizacijske skupine, koja je u trenutnoj niti, i nije trenutna kvantizacijska skupina, generira pomoću kvantizacijskog parametra susjedne jedinice kodiranja kvantizacijske skupine u trenutnoj niti, pri čemu je svaka od trenutnih niti i sljedećih niti između mnoštva niti sadržana u odsječku, pri čemu je predviđeni QP prve kvantizacijske skupine u svakom od mnoštva niti početni QP na razini odsječka.
A non-limiting list of exemplary materials for inclusion in the polymer matrix includes polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubber-like synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene-vinyloxyethanol copolymer, silicones including silicone copolymers such as polysiloxane-polymethacrylate copolymers, cellulose polymers (e.g ., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof Exemplary materials for inclusion in the polymer matrix layer are silicone elastomers of the general polydimethylsiloxane structures, (e.g ., silicone polymers). 
Bezgranični popis primjera materijala za uključivanje u polimerni matriks uključuje polietilen, polipropilen, etilen/propilen kopolimere, etilen/etilakrilat kopolimere, etilenvinil acetat kopolimere, silikone, gumu, gumi slične sintetičke homo-, ko- ili blok polimere, poliakrilne estere i njihove kopolimere, poliuretane, poliizobutilen, klorirani polietilen, polivinilklorid, vinil klorid-vinil acetat kopolimer, polimetakrilat polimer (hidrogel), poliviniliden klorid, poli(etilen tereftalat), etilen-vinil alkohol kopolimer, etilen-viniloksietanol kopolimer, silikone uključujući silikon kopolimere kao što su polisiloksan-polimetakrilat kopolimeri, polimere celuloze (npr., etil celuloza, te estere celuloze), polikarbonate, politetrafluoretilen i njihove mješavine. Primjeri materijala za uključivanje u sloj polimernog matriksa su silikon elastomeri općenitih struktura polidimetilsiloksana, (npr., polimeri silikona).
Pharmaceutical composition according to claim 2 in form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, dispersion or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku kreme, gela, suspenzije, masti, paste, disperzije ili emulzije.
An antibody or antigen-binding fragment thereof, which specifically binds human interleukin-6 receptor (hIL-6R) with a KD of 500 pM or less, as measured by surface plasmon resonance, wherein the heavy chain CDRs and the light chain CDRs comprise: 
Antitijelo ili njegov fragment koji se veže na antigen, koji se specifično veže na receptor humanoginterleukina 6 (hIL-6R) sa konstantom KD od 500 pM ili manje, izmjereno površinskom plazmon rezonancijom, naznačen time, da:
The method of any one of items 1-11, wherein the HCC is liver cell carcinoma, fibrolamellar variant of HCC, or mixed hepatocellular cholangiocarcinoma. The method any one of items 1-11, wherein the HCC is early stage HCC, non-metastatic HCC, primary HCC, advanced HCC, locally advanced HCC, metastatic HCC, HCC in remission, recurrent HCC, HCC in an adjuvant setting, or HCC in a neoadjuvant setting. 
Pripravak ili kombinacija za uporabu prema bilo kojem od zahtjeva 1-8, gdje je HCC karcinom stanica jetre, fibrolamelarna varijanta HCC-a, miješani hepatocelularni kolangiokarcinom, HCC ranog stadija, ne-metastatski HCC, primarni HCC, uznapredovali HCC, lokalno uznapredovali HCC, metastatski HCC, HCC u remisiji, ponavljajući HCC, HCC u adjuvansnom okruženju, ili HCC u ne-adjuvansnom okruženju.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The explosion proof and environment protective gas refueling equipment of Claim 7, characterized in that said skid (400) is fixed onto an anti-collision foundation to form a ground gas refueling equipment, or it is attached with the elevating mechanism of a gas refueling machine (X) and the tunnel base of tank pool to form an underground gas refueling equipment, or it is connected with the fixed platform of a vehicle body or ship hull to form a vehicle/ship mounted gas refueling equipment, or is fixed on the inner bottom plate of a container to form a container mounted type gas refueling equipment. 
Oprema za nadolijevanje plina koja je otporna na eksploziju i štiti okoliš prema zahtjevu 7, naznačena time da je navedeni klizač (400) učvršćen na protu-kolizijski temelj da se dobije nadzemna oprema za nadolijevanje plina, ili je spojen s podiznim mehanizmom stroja za nadolijevanje plina (X) i bazom tunela bazena spremnika da se dobije podzemna oprema za nadolijevanje plina, ili je povezan sa nepomičnom platformom tijela vozila ili oplatom broda da se dobije oprema za nadolijevanje plina postavljena na vozilo/brod, ili je učvršćen na unutrašnju donju ploču spremnika da se dobije tip opreme za nadolijevanje plina koji je postavljen na spremnik.
The mixture of claim 22, wherein the mixture comprises less than 30 ppm of metal ion impurities. 
Smjesa prema patentnom zahtjevu 22, naznačena time, da smjesa sadrži manje od 30 ppm nečistoća metalnim ionima.
A method as in 12, different with the respect that coagulation is carried out in closed tanks for 2-10 hours, constantly using gentle stirring. 
Postupak prema zahtjevu 6, naznačeno time da je koauglacija provedena u zatvorenim spremnicima kroz 2 do 10 sati, uz nesprestano lagano mješanje.
Use according to claim 9, wherein the osmolality adjusting agent is selected from the group consisting of glucose, fructose, mannose, sucrose, glycerol, erythritol, mannitol, sorbitol, inositol, threitol, xylitol, and maltitol. 
Jota-karagenan u antivirusno učinkovitoj količini za upotrebu prema patentnom zahtjevu 9, naznačeno time da je sredstvo za podešavanje osmolalnosti odabrano iz skupine koju čine glukoza, fruktoza, manoza, saharoza, glicerol, eritritol, manitol, sorbitol, inozitol, treitol, ksilitol i maltitol.
A compound according to any one of claims 1 to 26 for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes. 
Spoj prema bilo kojem zahtjevu od 1 do 29, naznačen time, da se koristi u postupku liječenja metabolički pripadajućih poremećaja kod ljudskog ili životinjskog tijela primjenom terapije, gdje je navedeni metabolički pripadajući poremećaj izabran iz skupine koju čine: dislipidemija, ateroskleroza, koronarno srčano oboljenje, inzulinska rezistencija i dijabetes tipa 2.
The process of claim 8, wherein the non-nucleophilic base is triethylamine. 
Postupak iz patentnog zahtjeva 4, u kome je ne-nukleofilna baza trietilamin.
Accessory according to claim 11 when depending upon claim 10, wherein the side appendix is configured and arranged so as to overlap at least partially the appendices configured to reach the palm surface of the wrist (PL). 
Pribor u skladu s patentnim zahtjevom 11 kada ovisi o patentnom zahtjevu 10, naznačen time, da je bočni dodatak oblikovan i postavljen tako da barem djelomično preklapa dodatke oblikovane da dosegnu površinu dlana zapešća (PL).
The method according to claim 6, wherein the tablet is a film-coated tablet. A method of treating Clostridium difficile infection (CDI) or Clostridium difficile associated diarrhea or disease (CDAD) in a patient according to a dosage regimen selected from the group consisting of: 
Farmaceutski pripravak, koji sadrži spoj tiakumicina, njegov stereoizomer, njegov polimorf ili njegov farmaceutski prihvatljiv solvat, za upotrebu u oralnom liječenju infekcija sa Clostridium difficile (CDI) ili proljeva ili bolesti povezane s Clostridium difficile (CDAD) kod pacijenta u skladu s režimom doziranja koji je odabran iz skupine koja sadrži:
preparing the Leishmania Ribosomal Protein Extract from the obtained cytosolic extract by submitting he cytosolic extract to high speed centrifugation at 90,000 rpm for 30 min at 4 °C in a Beckman TL100.3 rotor and resuspend the obtained pellet in buffer B comprising 20 mM Tris-HCl, pH 7.4, 500 mM AcNH4, 100 mM MgCl2, 5mM B-mercaptoethanol and centrifuged through a discontinuous sucrose gradient (20/40%) in buffer B at 90,000 rpm at 4 °C in a TL100.3 rotor. 
C) pripremom Leishmania ekstrakta ribosomskog proteina iz dobivenog citosolskog ekstrakta podvrgavanjem citosolskog ekstrakta centrifugiranju pri visokoj brzini na 90000 rpm kroz 30 min na 4*C€ u Beckman TL100.3 rotoru i resuspendiranje dobivenog taloga u puferu B koji obuhvaća 20 mM Tris-HCI, pH 7.4, 500 mM AcNH,, 100 mM MgCl, 5 mM f-merkaptoetanola i centrifugiranjem u diskontinuiranom gradijentu sukroze (20/40%) u puferu B na 90000 rpm na 4*C u TL100.3 rotoru.
The pharmaceutical compositions of rifaximin t are useful in the treatment or prevention of intestinal infections, for example, Escherichia coli, Clostridium difficile, and of traveller's diarrhoea, infectious diarrhoea and other intestinal disorders, for example, Crohn's disease, irritable bowel syndrome (IBS), enteritis, enterocolitis, diverticulitis, syndrome of the overgrowth of bacteria in the small intestine (SIBO), colitis, pancreatic insufficiency, chronic pancreatitis, hepatic encephalopathy, functional gastrointestinal disorders, functional dyspepsia with diarrhoea and other infections, for example, vaginal infections. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju crijevnih infekcija koje uzrokuju bakterije Escherichia coli ii Clostridium difficile, putničkog proljeva, zaraznog proljeva, crijevnog poremećaja poput Crohnove bolesti, sindroma iritabilnih crijeva (IBS), enteritisa, enterokolitisa, divertikulitisa, sindroma prerastanja bakterija u tanko crijevo (SIBO), kolitisa, insuficijencije gušterače, kroničnog pankreatitisa, hepatične encefalopatije, funkcionalnih gastrointestinalnih poremećaja, funkcionalne dispepsije uz proljev, te vaginalnih infekcija.
The base station apparatus according to claim 1, wherein said allocating unit allocates DVRBs with consecutive DVRB numbers to the mobile station. 
Integrirani krug sukladno jednom od zahtjeva 1 do 5, naznačen time da su u prvoj dodjeli DVRB-ovi s uzastopnim DVRB brojevima dodijeljeni aparatu mobilnoj stanici.
or a pharmaceutically acceptable salt of either of the foregoing. 
ili farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih spojeva.